MedTrace Logo

Transdermal Basal Insulin Patch Study in Type 1 Diabetes

NCT00519623 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 9

Last updated 2010-12-30

Study results available
· View outcomes & findings →

Summary

This study is designed to evaluate the pharmacokinetics/pharmacodynamics of an investigational basal insulin patch in type 1 diabetes patients.

Conditions

Interventions

OTHER

PassPort(R) Transdermal Insulin Delivery System

The PassPort(R) Transdermal Insulin Delivery System is a drug-device combination product used to create micropores in the skin to enable transdermal delivery of insulin.

Sponsors & Collaborators

  • Altea Therapeutics

    lead INDUSTRY

Principal Investigators

  • Vicky Spratlin, M.D. · Altea Therapeutics

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-08-31
Primary Completion
2007-11-30
Completion
2007-12-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00519623 on ClinicalTrials.gov